LINDA DANIEL-DIM: Open Payments
NPI 1962174896 · LEAVENWORTH, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$197 in 8 payments from 7 companies in 2025. Trend: 2023 $370 · 2024 $678 · 2025 $197
Food & beverage: $197
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 1 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| Alkermes, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
Products named: REXULTI, INVEGA SUSTENNA, COBENFY, INGREZZA, ARISTADA, CAPLYTA.
Industry payments across KS — which companies pay providers there.
